These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37289470)

  • 1. Changes to Primary End Points in Randomized Clinical Trials on Immune Checkpoint Inhibitors in Urothelial, Renal Cell, and Lung Cancers: A Systematic Review.
    Richters A; Yildirim H; Booth CM; Vera Badillo FE; Kiemeney LALM; Aben KKH
    JAMA Oncol; 2023 Aug; 9(8):1144-1147. PubMed ID: 37289470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.
    Mori K; Yanagisawa T; Fukuokaya W; Iwatani K; Matsukawa A; Katayama S; Pradere B; Laukhtina E; Rajwa P; Moschini M; Albisinni S; Krajewski W; Cimadamore A; Del Giudice F; Teoh J; Urabe F; Kimura S; Murakami M; Tsuzuki S; Miki J; Miki K; Shariat SF; Kimura T;
    Int J Urol; 2024 Jan; 31(1):25-31. PubMed ID: 37840031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis.
    Zhang R; Zhu J; Liu Y; Xin Y; Wang Y; Niu K; Wei H
    Medicine (Baltimore); 2021 Mar; 100(10):e19713. PubMed ID: 33725808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
    Front Immunol; 2021; 12():731546. PubMed ID: 34484242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review.
    Malone E; Barua R; Meti N; Li X; Fazelzad R; Hansen AR
    Cancer Med; 2021 Aug; 10(15):5031-5040. PubMed ID: 34184416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC.
    Ciccolini J; Benzekry S; Barlesi F
    Br J Cancer; 2020 Aug; 123(3):337-338. PubMed ID: 32541872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model: A Systematic Review.
    Filleron T; Bachelier M; Mazieres J; Pérol M; Meyer N; Martin E; Mathevet F; Dauxois JY; Porcher R; Delord JP
    JAMA Netw Open; 2021 Dec; 4(12):e2139573. PubMed ID: 34932105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
    Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
    Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis.
    Petrelli F; Ferrara R; Signorelli D; Ghidini A; Proto C; Roudi R; Sabet MN; Facelli S; Garassino MC; Luciani A; Roviello G
    Immunotherapy; 2021 May; 13(7):621-631. PubMed ID: 33775103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
    Li W; Jiang J; Huang L; Long F
    Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
    J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials.
    Tong ZQ; Wu DY; Liu D; Dong M
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1079-1088. PubMed ID: 33564898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.
    Tian Y; Zhai X; Yan W; Zhu H; Yu J
    Cancer Med; 2021 Jan; 10(1):3-14. PubMed ID: 33230935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors in GBM.
    Lee EQ
    J Neurooncol; 2021 Oct; 155(1):1-11. PubMed ID: 34599480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC].
    El-Ghazzi N; Lavaud P
    Bull Cancer; 2021 Mar; 108(3):231-233. PubMed ID: 33622569
    [No Abstract]   [Full Text] [Related]  

  • 18. Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients.
    Kubo T; Watanabe H; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Rai K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2020 Dec; 50(12):1447-1453. PubMed ID: 32869100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis.
    Wu LG; Zhou DN; Wang T; Ma JZ; Sui H; Deng WL
    Medicine (Baltimore); 2021 Mar; 100(12):e25145. PubMed ID: 33761681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.